HK1224206A1 - 用於治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物 - Google Patents

用於治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物 Download PDF

Info

Publication number
HK1224206A1
HK1224206A1 HK16112567.0A HK16112567A HK1224206A1 HK 1224206 A1 HK1224206 A1 HK 1224206A1 HK 16112567 A HK16112567 A HK 16112567A HK 1224206 A1 HK1224206 A1 HK 1224206A1
Authority
HK
Hong Kong
Prior art keywords
berberine
rosacea
dermatitis
topical pharmaceutical
related skin
Prior art date
Application number
HK16112567.0A
Other languages
English (en)
Chinese (zh)
Inventor
洪舜鬱
洪舜郁
鍾文宏
锺文宏
張子文
张子文
Original Assignee
德安生医有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德安生医有限公司 filed Critical 德安生医有限公司
Publication of HK1224206A1 publication Critical patent/HK1224206A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK16112567.0A 2009-06-30 2016-11-01 用於治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物 HK1224206A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22172509P 2009-06-30 2009-06-30
US61/221,725 2009-06-30

Publications (1)

Publication Number Publication Date
HK1224206A1 true HK1224206A1 (zh) 2017-08-18

Family

ID=43410481

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16112567.0A HK1224206A1 (zh) 2009-06-30 2016-11-01 用於治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物

Country Status (16)

Country Link
US (1) US9486402B2 (enExample)
EP (1) EP2448577B1 (enExample)
JP (2) JP6159084B2 (enExample)
KR (3) KR20170116231A (enExample)
CN (2) CN102481290A (enExample)
AU (1) AU2010268647B2 (enExample)
BR (1) BRPI1012128A2 (enExample)
CA (1) CA2766834C (enExample)
ES (1) ES2600909T3 (enExample)
HK (1) HK1224206A1 (enExample)
IL (1) IL217264A (enExample)
MX (1) MX344787B (enExample)
NZ (1) NZ597645A (enExample)
PL (1) PL2448577T3 (enExample)
RU (2) RU2533458C2 (enExample)
WO (1) WO2011000218A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
TW201538156A (zh) * 2013-12-19 2015-10-16 Twi Biotechnology Inc 小蘗鹼配方及其用途
AU2016282800A1 (en) * 2015-06-24 2018-02-01 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
EP3445330B1 (en) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of gram negative species to treat atopic dermatitis
EP3570835B1 (en) * 2017-01-19 2023-08-09 TWI Biotechnology, Inc. Diacerein for preventing or treating immunoinflammatory dermal disorders
EP3398448A1 (en) 2017-05-05 2018-11-07 Vall Garraf, S.L. Fattening additive for animal nutritional composition
CN111601617A (zh) 2017-12-13 2020-08-28 上海岸阔医药科技有限公司 一种用于预防或治疗与egfr 被抑制相关疾病的方法
JP7520366B2 (ja) 2018-04-16 2024-07-23 オンクオリティー ファーマシューティカルズ チャイナ リミテッド 腫瘍療法の副作用の予防または治療方法
EP3784260A4 (en) * 2018-04-18 2022-03-09 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions
CN108329310A (zh) * 2018-05-07 2018-07-27 深圳市迪克曼科技开发有限公司 黄藤素的制备方法
KR20210013080A (ko) 2018-05-11 2021-02-03 포르테 서브시디어리, 인크. 피부 병태의 치료를 위한 조성물
CN110882246B (zh) * 2018-09-08 2022-12-23 西南大学 不同生物活性的黄连生物碱的提取方法及应用
JP2020045338A (ja) * 2018-09-12 2020-03-26 大正製薬株式会社 外用組成物
IL281761B2 (en) 2018-09-25 2025-09-01 Ponce De Leon Health Designated Activity Company Process for preparing calcium alpha-ketoglutarate
JP6535146B1 (ja) * 2019-03-08 2019-06-26 佐藤製薬株式会社 皮膚バリア機能改善剤
RU2697854C1 (ru) * 2019-05-14 2019-08-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ комбинированной наружной терапии эритематозно-папулезной розацеа
CN113440613A (zh) * 2020-03-26 2021-09-28 轶诺(浙江)药业有限公司 小檗碱类似物与jak抑制剂在胃肠道炎症性疾病治疗中的用途
CN116370469A (zh) * 2023-04-27 2023-07-04 常州大学 四氢小檗碱类化合物对trpv3的抑制应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150920A (ja) * 1984-08-20 1986-03-13 Ichimaru Fuarukosu Kk 黄柏抽出エキス含有液の製造法
JPS63179812A (ja) * 1987-01-22 1988-07-23 Shiseido Co Ltd 皮膚外用剤
JP2609564B2 (ja) * 1991-05-31 1997-05-14 政夫 斎藤 アレルギー性皮膚炎用クリーム及びその製造方法
CN1085600A (zh) * 1993-07-07 1994-04-20 南宁市迪生新技术研究所 防治性病、传染病的杀菌保健香皂和浴液
CN1182788A (zh) * 1997-02-03 1998-05-27 熊光明 一种防治性病传染病的保健洗涤用品
US6482839B1 (en) 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
JP2001335485A (ja) * 2000-05-31 2001-12-04 Pola Chem Ind Inc メラノサイトのデンドライトの伸長抑制剤及びそれを含有する化粧料
KR20030082200A (ko) * 2002-04-17 2003-10-22 주식회사 엘지생활건강 베르베린을 함유하는 아토피성 피부염 예방 및 완화용조성물
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
WO2004093876A2 (en) * 2003-04-03 2004-11-04 The Board Of Trustees Of The University Of Illinois Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders
US7205006B2 (en) * 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
KR101045658B1 (ko) 2003-11-17 2011-07-01 쎄데르마 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물
US20050158404A1 (en) 2003-11-18 2005-07-21 Goodless Dean R. Composition and method for treatment of acne
EP1591125A1 (de) * 2004-04-19 2005-11-02 Universitätsklinikum Freiburg Pharmazeutische Zusammensetzung enthaltend Extrakte aus Flechten und Johanniskraut
US20060286054A1 (en) * 2005-06-15 2006-12-21 Apollo Pharmaceutical, Inc. Pharmaceutical compositions for the treatment of psoriasis
CN100441183C (zh) * 2005-08-29 2008-12-10 中国医学科学院皮肤病研究所 盐酸13-己基小檗碱和盐酸13-己基巴马汀制备治疗湿疹、皮炎和银屑病的药物用途
DE202010004750U1 (de) * 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut

Also Published As

Publication number Publication date
MX2011014006A (es) 2012-06-12
RU2014136492A (ru) 2016-03-27
JP6159084B2 (ja) 2017-07-05
EP2448577A4 (en) 2012-12-26
CA2766834C (en) 2017-04-25
JP2012531448A (ja) 2012-12-10
RU2533458C2 (ru) 2014-11-20
US9486402B2 (en) 2016-11-08
WO2011000218A1 (en) 2011-01-06
CN105534978A (zh) 2016-05-04
US20120165357A1 (en) 2012-06-28
CA2766834A1 (en) 2011-01-06
ES2600909T3 (es) 2017-02-13
PL2448577T3 (pl) 2017-02-28
MX344787B (es) 2017-01-05
AU2010268647B2 (en) 2015-01-15
KR101699572B1 (ko) 2017-01-24
KR20170116231A (ko) 2017-10-18
NZ597645A (en) 2014-03-28
CN102481290A (zh) 2012-05-30
IL217264A (en) 2017-01-31
KR20170010442A (ko) 2017-01-31
IL217264A0 (en) 2012-02-29
EP2448577A1 (en) 2012-05-09
EP2448577B1 (en) 2016-09-14
RU2671492C2 (ru) 2018-11-01
AU2010268647A1 (en) 2012-02-09
KR20120047240A (ko) 2012-05-11
RU2012102898A (ru) 2013-08-10
JP2017082019A (ja) 2017-05-18
BRPI1012128A2 (pt) 2016-03-29

Similar Documents

Publication Publication Date Title
HK1224206A1 (zh) 用於治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物
US10406120B2 (en) Methods and compositions for treating kidney disorders
JP2017019806A (ja) Ｈｉｖ関連の下痢を治療するための方法および組成物
CN108853403A (zh) 特定草药制剂的治疗性组合物及其用途
JP2016505561A (ja) Ｈｉｖ関連下痢を治療する方法および組成物
Vyjayanthi et al. Evaluation of anti-dandruff activity and safety of polyherbal hair oil: An open pilot clinical trial
TWI746701B (zh) 用於治療異位性皮膚炎的方法和組成物
KR20210036369A (ko) 자외선으로부터 피부를 보호하기 위한 라이코펜 조성물 및 방법
CN104220083A (zh) 用于治疗动脉硬化性血管疾病的方法和组合物
CN114366732B (zh) 泰妙菌素在制备用于治疗银屑病的药物中的应用
CN119925406A (zh) 一种治疗特应性皮炎的外用制剂及其制备方法和应用
JP5678566B2 (ja) 乾癬予防治療剤
CN104394874A (zh) 用于治疗动脉硬化性血管病的方法和组合物
CN102824349A (zh) 丹参酮ⅱa在制备治疗银屑病药物中的应用
HK1187539A (en) Methods and compositions for treating kidney disorders
HK40008168B (en) Methods and compositions for treating atopic dermatitis
KR20170050540A (ko) 메트포민을 유효성분으로 포함하는 피부질환 예방 또는 치료용 약학적 조성물
HK1196268B (zh) 特定草药制剂的治疗性组合物及其用途
EP2845591A1 (en) Use of trifluoroacetic acid as keratolytic agent to treat hyperkeratotic skin lesions

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF ENGLISH NAME OF INVENTOR FROM HUANG, SHUEN-LU T

Effective date: 20180403